Through inhibition of these oncogenic kinases, imatinib is effective in the treatment of BCR–ABL—positive leukemia, gastrointestinal stromal tumor, and hypereosinophilic syndrome, respectively. Here, ABL1 is linked to gastrointestinal stromal tumor.